In race to lead the TIG­IT pack in I/O, Roche de­liv­ers pos­i­tive PhII da­ta — but big ques­tions linger

Ex­pec­ta­tions over Roche’s an­ti-TIG­IT drug tiragolum­ab have been grow­ing steadi­ly in the buildup to AS­CO. As the lead drug in the field pur­su­ing sec­ond-gen­er­a­tion sta­tus in im­muno-on­col­o­gy, it marks a po­ten­tial ma­jor ad­vance over the first gen­er­a­tion of I/O drugs in the mar­ket.

And on Wednes­day’s da­ta drop, the phar­ma gi­ant’s big sub Genen­tech de­liv­ered the da­ta, which was quick­ly — and not al­ways fa­vor­ably — com­pared close­ly with Mer­ck’s dom­i­nant drug Keytru­da.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.